* Surrozen Inc SRZN.OQ reported a quarterly adjusted loss
of 44
cents per share for the quarter ended September 30, higher
than the same quarter last year, when the company reported EPS
of $-5.10. The mean expectation of two analysts for the quarter
was for a loss of $2.46 per share. Wall Street expected
results to range from $-2.77 to $-2.16 per share.
* Reported revenue was zero; analysts expected zero.
* Surrozen Inc's reported EPS for the quarter was a loss
of 44
cents.
* The company reported a quarterly loss of $1.43 million.
* Surrozen Inc shares had fallen by 8.7% this quarter and
gained 16.4% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 9% in
the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Surrozen Inc is
33.00
This summary was machine generated from LSEG data November 6 at
11:19 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -2.46 -0.44 Beat
Jun. 30 2024 -2.79 -1.54 Beat
Mar. 31 2024 -4.25 -4.24 Beat
Dec. 31 2023 -3.00 -4.41 Missed